Ticker LaunchFiled, not priced · EXXL
Exxel Pharma, INC.
Exxel Pharma, INC. publicly filed a registration statement on Form S-1 on Sep 19, 2025 for a proposed initial public offering on NYSE American under the ticker EXXL, and has not yet priced. Its latest amendment was filed on Feb 2, 2026. Underwriters named in the filing: Joseph Gunnar.
Exxel Pharma, INC. is a biopharmaceutical company developing therapeutics for neuronal hypersensitivity disorders. Its lead candidate, EX937, is a small molecule that selectively inhibits the enzyme FAAH outside the central nervous system, being developed for refractory chronic cough.
- Status
- Filed, not priced
- Ticker
- EXXL
- Exchange
- NYSE American
- First filed
- Sep 19, 2025
- Latest amendment
- Feb 2, 2026
- Underwriters
- Joseph Gunnar
- Sector
- Biotech & pharma
More on this listing for subscribers
- Amendment history
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 19, 2025
- Latest amendment Feb 2, 2026
- All filings on EDGAR CIK 2046638
Other companies in the IPO pipeline
- Seahawk Recycling Holdings, Inc.Sep 25, 2025
- CSC Collective Holdings LtdSep 22, 2025
- Guident Corp.Sep 18, 2025
- Global Development Engineering Co LtdSep 16, 2025
- Amatuhi Holdings, Inc.Sep 15, 2025
- Encore Medical, Inc.Sep 15, 2025